Virpax Pharmaceuticals, Inc. (VRPX)
NASDAQ: VRPX · Real-Time Price · USD
0.620
+0.003 (0.46%)
Nov 21, 2024, 12:03 PM EST - Market open
Virpax Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 |
| Cash & Equivalents | 0.02 | 9.14 | 19 | 36.84 | 0.05 | 0.04 | Upgrade
|
| Cash & Short-Term Investments | 0.02 | 9.14 | 19 | 36.84 | 0.05 | 0.04 | Upgrade
|
| Cash Growth | -99.86% | -51.87% | -48.44% | 67134.82% | 31.92% | -14.13% | Upgrade
|
| Prepaid Expenses | 0.29 | 0.2 | 0.18 | 0.16 | 0.01 | 0.01 | Upgrade
|
| Other Current Assets | - | 0.28 | 0.5 | 2.57 | 0 | - | Upgrade
|
| Total Current Assets | 0.3 | 9.63 | 19.67 | 39.57 | 0.07 | 0.05 | Upgrade
|
| Long-Term Deferred Charges | - | - | - | - | 0.39 | - | Upgrade
|
| Total Assets | 0.3 | 9.63 | 19.67 | 39.57 | 0.47 | 0.05 | Upgrade
|
| Accounts Payable | 2.36 | 0.02 | 0.04 | 0.02 | 0.02 | 0 | Upgrade
|
| Accrued Expenses | - | 1.68 | 1.06 | 2.07 | 3.08 | 1.5 | Upgrade
|
| Short-Term Debt | - | - | - | - | - | 1.26 | Upgrade
|
| Current Portion of Long-Term Debt | - | - | - | - | 0.54 | - | Upgrade
|
| Current Income Taxes Payable | - | - | - | - | 0.01 | 0.01 | Upgrade
|
| Other Current Liabilities | - | 6 | 2 | - | - | - | Upgrade
|
| Total Current Liabilities | 2.36 | 7.69 | 3.09 | 2.09 | 3.66 | 2.78 | Upgrade
|
| Long-Term Debt | - | - | - | - | 1.02 | - | Upgrade
|
| Total Liabilities | 2.36 | 7.69 | 3.09 | 2.09 | 4.68 | 2.78 | Upgrade
|
| Common Stock | 0 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Additional Paid-In Capital | 66.17 | 61.48 | 60.93 | 60.19 | 6.43 | 3.58 | Upgrade
|
| Retained Earnings | -68.22 | -59.54 | -44.35 | -22.7 | -10.65 | -6.31 | Upgrade
|
| Shareholders' Equity | -2.05 | 1.93 | 16.58 | 37.48 | -4.22 | -2.73 | Upgrade
|
| Total Liabilities & Equity | 0.3 | 9.63 | 19.67 | 39.57 | 0.47 | 0.05 | Upgrade
|
| Total Debt | - | - | - | - | 1.57 | 1.26 | Upgrade
|
| Net Cash (Debt) | 0.02 | 9.14 | 19 | 36.84 | -1.51 | -1.22 | Upgrade
|
| Net Cash Growth | -99.86% | -51.87% | -48.44% | - | - | - | Upgrade
|
| Net Cash Per Share | 0.01 | 7.81 | 16.22 | 55.18 | -4.86 | -4.18 | Upgrade
|
| Filing Date Shares Outstanding | 4.89 | 1.17 | 1.17 | 1.17 | 0.49 | 0.31 | Upgrade
|
| Total Common Shares Outstanding | 4.89 | 1.17 | 1.17 | 1.17 | 0.31 | 0.3 | Upgrade
|
| Working Capital | -2.05 | 1.93 | 16.58 | 37.48 | -3.59 | -2.73 | Upgrade
|
| Book Value Per Share | -0.42 | 1.65 | 14.15 | 32.00 | -13.41 | -9.05 | Upgrade
|
| Tangible Book Value | -2.05 | 1.93 | 16.58 | 37.48 | -4.22 | -2.73 | Upgrade
|
| Tangible Book Value Per Share | -0.42 | 1.65 | 14.15 | 32.00 | -13.41 | -9.05 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.